Paul Hengeveld – Research output — Erasmus University Rotterdam

If you made any changes in Pure these will be visible here soon.

5 Article
1 Comment/Letter to the editor
1 Review article

1 results

Filter

2022

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21 R110.
Hengeveld, P. J., Ertem, Y. E., Dubois, J. M. N., Mellink, C. H. M., van der Kevie-Kersemaekers, A-M., Evers, L. M., Heezen, K., Kolijn, P. M., Mook, O. R. F., Motazacker, M. M., Nasserinejad, K., Kersting, S., Westerweel, P. E., Niemann, C. U., Kater, A. P., Langerak, A. W. & Levin, M-D., 18 May 2022, (E-pub ahead of print) In: Leukemia. 36, 7, p. 1935-1938 4 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Open Access
File

9 Downloads (Pure)